Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
COVID-19 EventAnalyzer
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
EvaluatePharma
EvaluatePharma Vision
Japan Drug Forecasts
European Drug Forecasts
Epi Analyzer
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
November 04, 2019
Share price movers – October 2019
Edwin Elmhirst
Vantage Data Points
Related Companies
Achillion Pharmaceuticals
Assembly Biosciences
Botanix Pharmaceuticals
Constellation Pharmaceuticals
Cyclerion Therapeutics
Kiadis Pharma
Ra Pharmaceuticals
Reata Pharmaceuticals
ReNeuron Group
Savara Pharmaceuticals
Download PDF
Share This Article
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
April 16, 2020
Evaluate Vantage COVID-19 Report
February 20, 2020
Evaluate Vantage Pharma, Biotech & Medtech 2019 in Review
Related Articles
October 16, 2019
Alexion pays Achillion a $930m complement
October 10, 2019
UCB goes to Ra for a complementary approach
August 06, 2019
Share price movers – July 2019
July 03, 2019
Share price catalysts: June 2019
December 18, 2018
Achillion’s first oral Soliris rival hits the buffers
Editor's Picks
April 22, 2020
Covid-19 antibody tests face a very specific problem
June 17, 2020
Big pharma sports smallest late-stage pipeline for a decade
June 05, 2020
How best to develop a liquid biopsy?
June 18, 2020
All still for play for in haemophilia gene therapy race
May 20, 2020
J&J holds its own on sales per employee
